Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

MKSAP 19 > Pulmonary and Critical Care Medicine > Flashcards

Pulmonary and Critical Care Medicine Flashcards

1
Q

Diagnostic Imaging pleural effusion

A
  1. CXR should be performed as the first test

2.U/S is a helpful addition to CXR for identification of small effusions

3.CT with contrast include the ability to detect small amounts of pleural fluid; the assessment of coexisting intrathoracic abnormalities, such as pulmonary masses and malignant pleural disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

multiseptated (loculated) pleural effusion is ……..

A

exudate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Indications for Diagnostic Thoracentesis

A

new effusion of unclear etiology and > 1 cm of fluid thickness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pleural fluid triglycerides, support the diagnosis of chylothorax if it’s

A

> 110 mg/dL (1.24 mmol/L)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Complicated parapneumonic effusions treatment

A
  • drainage.

Options for drainage include early surgical intervention via video-assisted thoracoscopic surgery and chest tube drainage with or without the combined use of intrapleural fibrinolytics and a mucolytic agent (deoxyribonuclease, or DNase).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Malignant Pleural Effusion treatment

A

Repeat therapeutic thoracentesis is appropriate for patients with poor prognosis (less than 3 months) and slow reaccumulation of fluid.

Patients with rapid reaccumulation of fluid and dyspnea should be offered more definitive management. Indwelling pleural catheters with intermittent outpatient drainage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Nonmalignant Pleural Effusion treatment

A

If diagnostic uncertainty persists, additional evaluation with imaging (chest CT with contrast) and possible thoracoscopy should be considered.

Options for management include tunneled pleural catheters, pleurodesis, or both after careful discussion with a multidisciplinary team.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

considered a large pneumothorax if

A

If the lung margin is greater than 2 cm away from the chest wall at the level of the hilum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Management of Pneumothorax
if <2 cm on chest radiograph, minimal symptoms

A

Needle aspiration or admit to hospital for observation and supplemental oxygen (PSP may be managed as an outpatient if good access to medical care)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Management of Pneumothorax
if >2 cm on chest radiograph, breathlessness, and chest pain

A

Insertion of a small-bore (<14 Fr) thoracostomy tube with connection to a high-volume low-pressure suction system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Management of Pneumothorax
if Cardiovascular compromise (hypotension, increasing breathlessness) regardless of size

A

Emergent needle decompression followed by thoracostomy tube insertion

Note: If persistent air leak (>48 hours), refer to an interventional pulmonologist or thoracic surgeon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Intervention to prevent recurrence of pneumothorax.

A

chemical and mechanical pleurodesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

in pneumothorax
1. Air travel should be avoided

2.scuba diving

A
  1. until complete resolution
  2. not recommended unless definitive therapy such as surgical pleurectomy has been applied.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pleural-fluid LDH level in exudative pleural effusion

A

> 2/3 upper limit of normal for serum LDH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Diagnoses suggested by elevated pleural fluid amylase

A

Pancreatitis, esophageal rupture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Pulmonary Hypertension definition

A

resting mPAP of 20 mm Hg or greater

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Classification of Pulmonary Hypertension

A
  1. PH (includes idiopathic and heritable disease, disease associated with use of drugs or toxins, connective tissue diseases, HIV infection, congenital heart disease, schistosomiasis, and portal hypertension; also includes vasoresponsive PAH and PAH attributable to pulmonary venoocclusive disease or pulmonary capillary hemangiomatosis)

2.PH due to left-sided heart disease

3.PH due to lung diseases or hypoxia

4.Chronic thromboembolic pulmonary hypertension and other pulmonary artery obstructions

5.PH with unclear or multifactorial causes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Evaluation of Suspected Pulmonary Hypertension

A
  1. ECHO (should not be used to confirm a PH diagnosis because is often inaccurate)

2.PFT, HRCT, Sleep Study

3.serologic tests for underlying connective tissue disease, hepatitis, and HIV are advised

  1. V/Q scan to evaluate for chronic thromboembolic PH

5.Right heart catheterization is essential to confirm a diagnosis of PH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

When V/Q scan suggests chronic thrombus, additional imaging to evaluate the extent of CTEPH is indicated.

A

Digital subtraction angiography

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

current guidelines recommend that patients with CTEPH undergo screening for

A

thrombophilia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Chronic Thromboembolic Pulmonary Hypertension (Group 4)
treatment

A

Anticoagulation and consideration of thromboendarterectomy are indicated for CTEPH.

Lifelong anticoagulant therapy is indicated in all patients to help prevent further thromboembolism.

In inoperable patients and those who have persistent PH after thromboendarterectomy, balloon pulmonary angioplasty or medical therapy (Riociguat) should be considered.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

apnea-hypopnea index : mid

A

5-14

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

apnea-hypopnea index moderate

A

15-30

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

apnea-hypopnea index severe

A

> 30

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
The most important risk factor for obstructive sleep apnea is
obesity
26
Overnight pulse oximetry for
asymptomatic with a low pretest probability, normal overnight oximetry might support the decision to avoid further testing.
27
OSA treatment
1.bariatric surgeon should be considered for patients with BMI ≥35 who have not benefited from or are intolerant of positive airway pressure therapy. 2. CPAP or BIPAP in hypoventilation syndrome
28
On polysomnography, absence of respiratory effort associated with loss of airflow for at least 10 seconds.
central apnea
29
Initial management of CSA
1. should target modifiable risk factors (reduction or elimination of opioids improves CSA &Medical optimization of heart failure) 2. CPAP may occasionally be useful, especially in patients with overlapping OSA 3. oxygen during sleep may be indicated for who have hypoxia during sleep, as well as for those who cannot use or tolerate CPAP
30
CPAP treatment alternative for mild/moderate OSA
Oral appliance
31
Diagnosis suggested by nocturnal absence of respiratory effort and airflow
CSA
32
DLCO Mild
> 60
33
DLCO moderate
40-60
34
DLCO severe
< 40
35
An increase from baseline in FEV1, FVC, or both of at least ............relative to the predicted value indicates a positive bronchodilator response
10%
36
in obstructive pattern FEV1/FVC ratio
< 0.70
37
TLC is normal or even increased in
pure obstructive disease
38
If FEV1 or FVC is reduced and the FEV1/FVC ratio is 0.70 or greater
restrictive pattern may be interpreted, but measurement of TLC is needed to confirm this. If TLC is less than 80% of predicted (or the lower limit of normal), a restrictive pattern is present.
39
coexisting obstructive and restrictive pulmonary disorders FEV1/FVC ratio >> TLC >>
low FEV1/FVC ratio (obstructive) and a low TLC (restrictive) are both present
40
In cases of suspected inaccurate pulse oximetry by finger probe, changing to
an earlobe probe or forehead probe is indicated.
41
Positive bronchial challenge test result
FEV1 > 0.2 ml or 12 %
42
Allergic Bronchopulmonary Aspergillosis diagnosis
1.presence of asthma 2.elevated IgE levels 3.positive skin tests to Aspergillus antigens 4.increased Aspergillus-specific IgE and IgG levels 5.either central bronchiectasis or infiltrates.
43
Allergic Bronchopulmonary Aspergillosis treatment
Management is aimed at 1.suppressing the enhanced immunologic response with systemic glucocorticoids 2.reducing the fungal antigenic burden with antifungal agents
44
target interleukin-5 (IL-5)
1. mepo (lizumab) 2. res (lizumab) 3. benra (lizumab)
45
anti-IgE biologic
omalizumab
46
inhibitor of IL-4 and IL-13
dupilumab
47
BA management in Step 1
SABA as needed Or ICS & SABA as needed
48
BA management in Step 2
Daily low dose ICS & SABA as needed Or ICS & SABA as needed
49
BA management in Step 3
Daily & as needed combination low dose ICS- formoterol
50
BA management in Step 4
Daily & as needed combination medium dose ICS - formoterol
51
BA management in Step 5
Daily medium to high dose ICS- LABA + LAMA & SABA as needed
52
BA management in Step 6
Daily high dose ICS - LABA + oral steroid + SABA as needed Consider add-on Anti IgE Anti IL5, Anti IL4/ IL13
53
Cystic Fibrosis is
autosomal recessive results in abnormally thick secretions that are difficult to clear.
54
the initial test for CF is
Sweat chloride testing Abnormal results on repeat testing are diagnostic of CF Genetic testing confirms the diagnosis and helps with prognosis.
55
treatment of CF
airway clearance antibiotic therapy nutritional support psychosocial support.
56
Bronchiectasis is diagnosed by
HRCT. Diagnostic criteria include an airway diameter that is greater than that of its accompanying vessel and lack of distal airway tapering
57
treatment of bronchiectasis focuses on
clearing the airway treating infections preventing exacerbations Patients should also be encouraged to exercise, which can improve airway clearance and symptoms. Surgical resection should be considered in patients who have localized disease with persistent symptoms despite therapy.
58
Treatment of Exacerbations of bronchiectasis
Therapy is guided by routine sputum and AFB culture results. Empiric antibiotic therapy is recommended and may be based on previous culture data until the results of the current sputum culture become available. If previous data are not available, a fluoroquinolone can be started to ensure Pseudomonas coverage until sputum culture results are available.
59
The 2023 guidelines recommend adding inhaled glucocorticoids in COPD if:
- if eosinophil count exceeds 300/uL, - if exacerbations are uncontrolled and the eosinophil count is > 100/uL - if the patient has significant asthmatic features along with COPD.
60
selective phosphodiesterase-4 inhibitor that is used to reduce the frequency of exacerbations in patients with severe COPD who have primarily symptoms of chronic bronchitis.
Roflumilast
61
Indications for long-term oxygen therapy
1. Hypoxia: PaO2 ≤55 mmHg (7.32 kPa) or SaO2 ≤88 % 2. In the presence of cor pulmonale PaO2 ≤59 mmHg (7.85 kPa) or SaO2 ≤89 % Hematocrit > 55 % Clinical evidence of right HF
62
Ideal patients for lung volume reduction therapy
1.upper-lobe-predominant emphysema, 2.FEV1 and DLCO of 20% of predicted or higher, and 3.low exercise tolerance after completion of pulmonary rehabilitation.
63
Antibiotic class for severe COPD with frequent exacerbations
Macrolide
64
LÖfgren syndrome
1.Acute 2. Erythema nodosum 3. Arthritis 4. Hilar adenopathy
65
Heerfordt Waldenström
1. Subacute to chronic 2. Fever 3. Parotid enlargement 4. Uveitis 5. Facial palsy
66
Asbestos exposure, progressive Dyspnea, pleurtic chest pain , bloody pleural effusion
Mesothelioma
67
Patient with silicosis are at risk concurrent…….infection
TB
68
1. Asbestosis involves the ……. Lung 2. Silicosis involves the ….. lung
1. Lower 2. Upper
69
recommend serologic testing to exclude CTD-associated DPLD.
Routine testing with CRP, ESR, ANA, RF, ACCP myositis panel.
70
smoking-related DPLDs, the primary management is
smoking cessation. Glucocorticoids may be considered with severe disease or in those with refractory symptoms.
71
treatment of Hypersensitivity Pneumonitis
Removal of exposure to the offending antigen Glucocorticoids and sometimes other immunosuppressants are often used for those with more severe symptoms.
72
Management of patients with IPF
oxygen supplementation for hypoxemia and antifibrotic therapies - nintedanib -pirfenidone
73
treatment of Cryptogenic Organizing Pneumonia
Patients with COP respond well to glucocorticoid therapy. Relapses of COP with tapering of glucocorticoids are common
74
treatment of Acute Interstitial Pneumonia
Management includes ventilatory support and critical care, as it does for patients with ARDS. often treated with high-dose glucocorticoid
75
Single Pulmonary Nodule Follow-Up <6 mm
low risk no f/u high risk at 12 months
76
Single Pulmonary Nodule Follow-Up 6 - 8 mm
6-12 months then 18-24 moths
77
Single Pulmonary Nodule Follow-Up > 8 mm
at 3 months with 1. CT or 2. PET or 3. tissue sampling
78
Solitary Subsolid Lung Nodule Follow-Up Pure ground glass & Part solid nodule
if < 6 mm no f/u Pure ground glass ≥6 mm CT at 6-12 months to confirm persistence, then CT every 2 years until 5 years Part solid nodule ≥6 mm CT at 3-6 months to confirm persistence; if unchanged and solid component remains <6 mm, annual CT should be performed for 5 years
79
types of lung cancer
1.small cell cancer ( smoker,cerntral,SIADH) 2.non-small cell cancer -adenocarcinoma (peripheral , non smoker) -large cell carcinoma (peripheral ) -squamous cell carcinoma ( smoker,cerntral)
80
Annual lung cancer screening should be performed in
patients aged 50 through 80 years who have no symptoms of lung cancer, have at least a 20-pack-year smoking history, and are current smokers or have quit within the last 15 years.
81
Cessation of lung cancer screening should be considered in
1.those who have not smoked in 15 years, 2.those with limited life expectancy, and 3.those who would not be candidates for or would not be willing to undergo surgery.
82
Diagnosis suggested by headache, nausea, disturbed sleep at altitude
Acute mountain sickness
83
Treatment for high-altitude cerebral edema
Dexamethasone, oxygen, descent
84
Drug treatments for high-altitude pulmonary edema
Nifedipine, PDE-5 inhibitor
85
Possible complication in air travel for patients with asthma or COPD
Pneumothorax
86
Oxygen saturation level requiring supplemental O2 during air travel
<92%
87
Test to determine need for supplemental O2 during air travel
Hypoxia altitude simulation testing
88
Enteral nutrition should start within
24 to 48 hours of admission.
89
Alleviate hypoxemia by MV
Increasing FIO2 Increasing PEEP
90
Improve respiratory alkalosis BY MV ( Hypocapnia )
Decreasing respiratory rate Decreasing tidal volume
91
Improve respiratory acidosis BY MV ( Hypercapnia)
Increasing respiratory rate Increasing tidal volume
92
Berlin definition of ARDS
1. Symptoms must have begun within 1 week of a known clinical insult 2. Bilateral opacities consistent with pulmonary edema on CXR 3. Respiratory failure ( not explained by HF or fluid overload) 4. Arterial pO2/FiO2 < 300 with PEEP at least 5
93
Severity of ARDS PaO2/FiO2 ration on MV settings PEEP >= 5
Mild 201- 300 Moderate 101-200 Severe =< 100
94
ARDS VENTILATOR SETTING
FiO2 100 % and lower < 60 % ASAP TV 6-8 ml /kg PEEP start at 5 and titrate to plateau pressure =< 30 cmH2O
95
CO low PCWP high SVR high Which type of shock
Cardiac shock
96
CO low PCWP low SVR high Which type of shock
Hypovolemic shock
97
CO high PCWP low SVR low Which type of shock
Distributive shock
98
Indication of prone position in ARDS
If pO2/FiO2 ratio < 150 and FiO2 at least 60 At least 12-16 hours a day
99
Therapeutic treatment of severe refractory respiratory failure resulting from ARDS
ECMO
100
Diagnosis of Hereditary angioedema by
1. Quantitive & functional levels of C1 esterase inhibitor and 2. C4 complement level
101
Treatment of malignant hyperthermia
1. DC the triggering agent 2.Active cooling 3.Muscle relaxant dantrolene every 5 to 10 minutes until muscle rigidity and hyperthermia resolve.
102
TREATMENT OF Serotonin syndrome
removing the offending agent and supportive care. Cyproheptadine is sometimes used if benzodiazepines fail to control symptoms.
103
TREATMNET OF Neuroleptic malignant syndrome
1. stopping the triggering agent (or reinstating the withdrawn dopaminergic agent) 2. active cooling 3. supportive care including IV fluid administration. 4. Evidence for pharmacotherapy is anecdotal, but options include benzodiazepines, dantrolene, and bromocriptine. Neuroleptic medications can be reintroduced after a waiting period of at least 2 weeks, usually at lower dose, with care to avoid dehydration and concomitant administration with lithium.
104
Neuroleptic Malignant Syndrome & Serotonin Syndrome
Neuroleptic Malignant Syndrome: tetrad of fever, mental status changes, dysautonomia AND muscle rigidity. Serotonin Syndrome: fever, mental status changes, dysautonomia, hyperreflexia, and other muscle abnormalities.
105
Patients with high levels of carboxyhemoglobin (25% and greater) and evidence of organ ischemia should be treated with
hyperbaric oxygen if possible.
106
Heat stroke treatment
1. Evaporative cooling ( water mist & fans ) 2. Immersion in ice water for only young patients when they remain severely symptomatic despite evaporative cooling. * acetaminophen is not effective for heat stroke
107
Diagnose glucocorticoid-responsive asthma with
fractional exhaled nitric oxide testing

MKSAP 19 (12 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions